This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The latest numbers from the MoneyTree Report from PricewaterhouseCoopers, The National VentureCapital Association, and Thomson Reuters have tallied up just under a billion dollars in venturecapital investments in the Southern California region in Q1 of this year, a very significant uptick from Q2 of 2011.
San Diego-based AvalonVentures , a venturecapital firm focused on early stage high tech, digital media, and life sciences firms, said today that it has closed on $200M in capital commitments for its latest fund. Avalon said that the fund, AvalonVentures IX, LP, is the ninth and largest fund for the company.
La Jolla-based venturecapital investor AvalonVentures has just received a $103M commitment to a new, $300M fund, according to a regulatory filing by the firm. Avalon invests in both life sciences and technology companies, and invests in seed an dearly stage companies. READ MORE>>.
Investments by venture capitalists in Southern California were up, both in terms of deals and dollars in Q2, according to the latest numbers from PricewaterhouseCoopers and the National VentureCapital Association (NVCA). The increasing venture activity seems to indicate a recovery in the outlook for startups here.
The second tranche of the company''s Series B came from investors AvalonVentures, Torrey Pines Investment and WuXi PharmaTech Investments. The technology behind the Avelas product is based on research conducted at UC San Diego. in a Series B funding. READ MORE>>.
Chumby has previously raised funding from AvalonVentures, JK&B Capital, Masthead Venture Partners, and O'Reilly AlphaTech Ventures. Chumby recently licensed the firm's technology to automotive software firm QNX Software Systems. The company is headed by Derrick Oien. READ MORE>>.
San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from AvalonVentures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients.
The latest numbers from the PricewaterhouseCoopers/National Venturecapital Association MoneyTree survey, which is based on data from Thomson Reuters, tallies $738.34M invested in Southern California in Q4 of 2011. The amount is up from $528.0M raised in Q4 of 2010, and up from the $652M invested in the region last quarter.
and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's AvalonVentures were investors in the round. READ MORE>>.
The startup--led by technology startup vet Derrick Oien--said the funding was led by Sinclair Digital Ventures, a division of Sinclair Broadcast Group. Also participating in the funding was AvalonVentures, New Enterprise Associates, and angels, including Kevin Plank (Under Armour) and Paul Palmieri (Millennial Media).
The funding came from Divergent Ventures, along with existing investors AvalonVentures. Bolt was most recently at Avamar Technologies, where he was CTO of the firm before its acquisition by EMC in 2006. The firm said the new funding brings its total raised to $5M. The firm is led by Rory Bolt. READ MORE>>.
in a Series A financing for the firm's biopharmaceuticals technology. According to the firm, the financing came from AvalonVentures LLC. San Diego-based Zacharon Pharmaceutical said today that it has raised $3.5M The firm also said it has received more than $2.2M in National Institutes of Health (NIH) research grants.
The funding was led by AvalonVentures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. Enlibrium said the technology has been exclusively licensed from UCLA. Enlibrium is being led by David Campbell, Ph.D. READ MORE>>.
PricewaterhouseCoopers and the National VentureCapital Association (NVCA) released their 2008 Q4 MoneyTree Report this evening, reporting that $28.3 Clean Technology saw a 52 percent increase in terms of dollars, and 16 percent growth in deal volume over 2007, reaching an investment level of $4.1 billion in the third quarter.
It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp., and San Diego’s AvalonVentures. Inbio Ventures, a venturecapital management company, represented Pharmstandard in the deal.
After Chumby, I was EIR for AvalonVentures, and was looking at a couple of different opportunities, ranging from 3D printing, to Machine-to-Machine communications, medical IT, and sports there. It did, and so we sat down and built a bunch of technology, and the next season we scored 20,000 games. I was at MP3.com,
After Chumby, I was EIR for AvalonVentures, and was looking at a couple of different opportunities, ranging from 3D printing, to Machine-to-Machine communications, medical IT, and sports there. It did, and so we sat down and built a bunch of technology, and the next season we scored 20,000 games. I was at MP3.com,
Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.
After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.
Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors AvalonVentures and Correlation Ventures joined in the round.
Xconomy is convening life sciences and technology founders, executives, investors, and entrepreneurs for an afternoon of fireside chats and solo talks at Human Impact of Innovation. What are the emerging opportunities for investors and executives on these topics, and what role will San Diego play in the advancement of these technologies?
After completing his MBA in 1985, Bock joined a now-defunct venture firm in Costa Mesa, CA. He found he didn’t enjoy being a traditional VC gatekeeper who said “yes” or “no” to startup pitches, according to his wife, Diane. “He It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s AvalonVentures.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content